Eam Investors, LLC Provention Bio, Inc. Transaction History

Eam Investors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$4.52 - $10.57 $1.25 Million - $2.92 Million	276,250 New	276,250 $2.92 Million
Q3 2020 Nov 13, 2020	SELL	$10.34 - $15.2 $558,566 - $821,104	-54,020 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$7.81 - $17.0 $441,452 - $960,908	-56,524 Reduced 51.13%	54,020 $762,000
Q1 2020 May 13, 2020	BUY	$5.42 - $17.75 $599,148 - $1.96 Million	110,544 New	110,544 $1.02 Million
Q4 2019 Feb 11, 2020	SELL	$5.84 - $14.9 $82,495 - $210,477	-14,126 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$6.83 - $13.0 $304,392 - $579,371	-44,567 Reduced 75.93%	14,126 $96,000
Q2 2019 Aug 14, 2019	BUY	$2.3 - $13.79 $134,993 - $809,376	58,693 New	58,693 $710,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.